The experimental cholesterol drug obicetrapib slowed Alzheimer's biomarkers, over 12 months in patients with cardiovascular disease, offering a potential new therapy.
Read at Medscape
Unable to calculate read time
Collection
[
|
...
]
Experimental Med May Slow Alzheimer's Biomarker Progression Briefly
Experimental Med May Slow Alzheimer's Biomarker Progression